Steroid Sparing Effect of 300IR House Dust Mite Sublingual Immunotherapy Tablet in Mite Allergic Rhinitis.

Of 1262 evaluable patients, ∼60% used at least one CS at baseline: 300IR = 373 and placebo = 396.

During treatment, the proportions of patients using rescue medication, oral AH1, and CS and of days with rescue medication use decreased in both groups, systematically in favor of 300IR (p < 0.05 at end-of-treatment).

Odds results indicated sublingual immunotherapy-patients were more likely not to use CS, whereas placebo-patients were more likely to use CS (p < 0.05 at end-of-treatment).

Those who were still using CS were taking fewer and lower doses than placebo-patients.